Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 25 11 2019
accepted: 20 01 2020
pubmed: 29 2 2020
medline: 4 4 2020
entrez: 29 2 2020
Statut: ppublish

Résumé

Several scoring systems have been proposed to predict the outcome of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). However, the application of these scores to a bridging to transplant setting is poorly validated. Evaluation of the applicability of prognostic scores for patients undergoing TACE in palliative intention vs. bridging therapy to liver transplantation (LT) is necessary. Between 2008 and 2017, 148 patients with HCC received 492 completed TACE procedures (158 for bridging to transplant; 334 TACE procedures in palliative treatment intention at our center and were analyzed retrospectively. Scores (ART, CLIP, ALBI, APRI, SNACOR, HAP, STATE score, Child-Pugh, MELD, Okuda and BCLC) were calculated and evaluated for prediction of overall survival. ROC analysis was performed to assess prediction of 3-year survival and treatment discontinuation. In patients receiving TACE in palliative intention most scores predicted OS in univariate analysis but only mSNACOR score (p = 0.006), State score (p < 0.001) and Child-Pugh score (p < 0.001) revealed statistical significance in the multivariate analysis. In the bridging to LT cohort only the BCLC score revealed statistical significance (p = 0.002). Clinical usability of suggested scoring systems for TACE might be limited depending on the individual patient cohorts and the indication. Especially in patients receiving TACE as bridging to LT none of the scores showed sufficiently applicability. In our study Child-Pugh score, STATE score and mSNACOR score showed the best performance assessing OS in patients with TACE as palliative therapy.

Identifiants

pubmed: 32107625
doi: 10.1007/s00432-020-03135-8
pii: 10.1007/s00432-020-03135-8
pmc: PMC7085483
doi:

Substances chimiques

Ethiodized Oil 8008-53-5
Doxorubicin 80168379AG
Carboplatin BG3F62OND5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1033-1050

Références

Hepatology. 2005 Apr;41(4):707-16
pubmed: 15795889
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3
pubmed: 9409568
J Vasc Interv Radiol. 2006 Oct;17(10):1619-24
pubmed: 17057003
Transplant Proc. 2009 May;41(4):1260-3
pubmed: 19460533
Am J Gastroenterol. 2008 Mar;103(3):597-604
pubmed: 17970836
Cancer. 2004 Aug 15;101(4):796-802
pubmed: 15305412
Dig Dis. 2014;32(6):711-6
pubmed: 25376288
PLoS One. 2012;7(10):e45066
pubmed: 23071507
J Hepatol. 2006 Apr;44(4):723-31
pubmed: 16488051
Cancer. 2000 Dec 1;89(11):2266-73
pubmed: 11147597
Hepatol Int. 2012 Oct;6(4):753-62
pubmed: 26201524
Hepatobiliary Pancreat Dis Int. 2016 Apr;15(2):152-7
pubmed: 27020631
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
PLoS One. 2014 Mar 07;9(3):e88182
pubmed: 24609114
Semin Liver Dis. 2005;25(2):181-200
pubmed: 15918147
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1305-15
pubmed: 14624154
Liver Int. 2016 Jan;36(1):92-9
pubmed: 25950442
Can J Gastroenterol. 2011 Aug;25(8):426-32
pubmed: 21912767
Int J Cancer. 1998 Dec 18;79(6):601-5
pubmed: 9842968
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1563-9
pubmed: 12823161
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Hepatology. 2003 Feb;37(2):429-42
pubmed: 12540794
Hepatology. 1994 May;19(5):1115-23
pubmed: 7513677
PLoS One. 2017 Jul 3;12(7):e0180408
pubmed: 28672011
N Engl J Med. 1995 May 11;332(19):1256-61
pubmed: 7708069
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Liver Transpl. 2006 Apr;12(4):665-73
pubmed: 16482577
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
HPB (Oxford). 2010 Apr;12(3):174-80
pubmed: 20590884
Gastroenterol Clin Biol. 2002 Aug-Sep;26(8-9):728-34
pubmed: 12434077
Major Probl Clin Surg. 1964;1:1-85
pubmed: 4950264
J Ayub Med Coll Abbottabad. 2017 Jul-Sep;29(3):378-383
pubmed: 29076665
J Hepatol. 2004 Jan;40(1):124-31
pubmed: 14672623
Hepatology. 2010 Apr;51(4):1274-83
pubmed: 20112254
Hepatology. 2000 Dec;32(6):1224-9
pubmed: 11093728
Chin Med J (Engl). 2015 Feb 5;128(3):316-21
pubmed: 25635426
J Hepatol. 2008;48 Suppl 1:S20-37
pubmed: 18304676
Liver Transpl. 2005 Jul;11(7):767-775
pubmed: 15973710
Oncotarget. 2016 Jul 12;7(28):44705-44718
pubmed: 27244889
BMC Cancer. 2018 Apr 27;18(1):489
pubmed: 29703174
Medicine (Baltimore). 2015 Nov;94(47):e1659
pubmed: 26632677
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Hepatology. 1999 Jan;29(1):62-7
pubmed: 9862851
World J Gastroenterol. 2014 Jul 7;20(25):8158-65
pubmed: 25009388
Cardiovasc Intervent Radiol. 2017 Oct;40(10):1559-1566
pubmed: 28488104
Hepatology. 2013 Jun;57(6):2261-73
pubmed: 23316013
Clin Res Hepatol Gastroenterol. 2016 Dec;40(6):705-714
pubmed: 27289168
J Natl Cancer Inst. 2008 May 21;100(10):698-711
pubmed: 18477802
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
J Vasc Interv Radiol. 2004 Nov;15(11):1209-18
pubmed: 15525739
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Cancer. 1985 Aug 15;56(4):918-28
pubmed: 2990661
Langenbecks Arch Surg. 2017 Sep;402(6):863-871
pubmed: 28755240
Zhonghua Yi Xue Za Zhi. 2016 Mar 8;96(9):716-9
pubmed: 27055511
Semin Liver Dis. 2008 Feb;28(1):110-22
pubmed: 18293281
PLoS One. 2014 Jun 06;9(6):e98782
pubmed: 24905210
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89
pubmed: 16305721
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
J Hepatol. 2014 Dec;61(6):1287-96
pubmed: 25016222
J Hepatol. 2014 Jan;60(1):118-26
pubmed: 24012941
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568

Auteurs

Marie Vogeler (M)

Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Isabelle Mohr (I)

Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Jan Pfeiffenberger (J)

Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Simon David Sprengel (SD)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Miriam Klauss (M)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Andreas Teufel (A)

Division of Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

De-Hua Chang (DH)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Christoph Springfeld (C)

Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Thomas Longerich (T)

Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Uta Merle (U)

Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Arianeb Mehrabi (A)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, INF 110, 69120, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Karl Heinz Weiss (KH)

Internal Medicine IV, Heidelberg University Hospital, Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany.

Markus Mieth (M)

Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, INF 110, 69120, Heidelberg, Germany. Markus.mieth@med.uni-heidelberg.de.
Liver Cancer Center Heidelberg (LCCH), Heidelberg University Hospital, Heidelberg, Germany. Markus.mieth@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH